Castle Biosciences, Inc. (CSTL) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $24.37. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CSTL = $2,068.57 (+8388.2% from the current price, the stock appears undervalued). Analyst consensus target is CSTL = $50 (+104.3% upside).
Valuation: CSTL trades at a trailing Price-to-Earnings (P/E) of -29.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.55.
Financials: revenue is $344M, +38.4%/yr average growth. Net income is $24M (loss), growing at -28.8%/yr. Net profit margin is -7% (negative). Gross margin is 68.7% (-7.9 pp trend).
Balance sheet: total debt is $37M against $471M equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 5.26 (strong liquidity). Debt-to-assets is 6.4%. Total assets: $579M.
Analyst outlook: 11 / 11 analysts rate CSTL as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 49/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
